{"id":127004,"date":"2021-08-31T14:23:51","date_gmt":"2021-08-31T21:23:51","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2021\/08\/nih-launches-study-of-extra-covid-19-vaccine-dose-in-people-with-autoimmune-disease"},"modified":"2021-08-31T14:23:51","modified_gmt":"2021-08-31T21:23:51","slug":"nih-launches-study-of-extra-covid-19-vaccine-dose-in-people-with-autoimmune-disease","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2021\/08\/nih-launches-study-of-extra-covid-19-vaccine-dose-in-people-with-autoimmune-disease","title":{"rendered":"NIH launches study of extra COVID-19 vaccine dose in people with autoimmune disease"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/nih-launches-study-of-extra-covid-19-vaccine-dose-in-people-with-autoimmune-disease2.jpg\"><\/a><\/p>\n<p>Trial also will test pausing immunosuppressive medication to improve antibody response.<\/p>\n<p>The National Institutes of Health has begun a clinical trial to assess the antibody response to an extra dose of an authorized or approved COVID-19 vaccine in people with autoimmune disease who did not respond to an original COVID-19 vaccine regimen. The trial also will investigate whether pausing immunosuppressive therapy for autoimmune disease improves the antibody response to an extra dose of a COVID-19 vaccine in this population. The Phase 2 trial is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, and is being conducted by the NIAID-funded Autoimmunity Centers of Excellence.<\/p>\n<p>\u201cMany people who have an autoimmune disease that requires immunosuppressive therapy have had a poor immune response to the authorized and approved COVID-19 vaccines, placing these individuals at high risk for the disease,\u201d said NIAID Director Anthony S. Fauci, M.D. \u201cWe are determined to find ways to elicit a protective immune response to the vaccines in this population. This new study is an important step in that direction.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Trial also will test pausing immunosuppressive medication to improve antibody response. The National Institutes of Health has begun a clinical trial to assess the antibody response to an extra dose of an authorized or approved COVID-19 vaccine in people with autoimmune disease who did not respond to an original COVID-19 vaccine regimen. The trial also [\u2026]<\/p>\n","protected":false},"author":621,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,1495],"tags":[],"class_list":["post-127004","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-health"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/127004","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/621"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=127004"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/127004\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=127004"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=127004"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=127004"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}